Document is current
Any future updates will be listed below
-
Authors
Jonas, Jost B. https://orcid.org/0000-0003-2972-5227
Xu, Liang
Wei, Wen Bin
Jonas, Rahul A.
Wang, Ya Xing
-
Funding
Funding for this research was provided by:
National Natural Science Foundation of China (81570835)
Beijing Municipal of Health Reform and Development Project (2019-4)
- License Information
-
More Information
Article History
Received: 18 January 2022
Revised: 2 March 2022
Accepted: 6 May 2022
First Online: 24 May 2022
Declarations
:
: All procedures were in accordance with the ethical standards of the Medical Ethics Committee of the Beijing Tongren Hospital and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Jost B. Jonas and Rahul A. Jonas: European patent EP 3 271 392 and US patent US 11,008,385: Agents for use in the therapeutic or prophylactic treatment of myopia or hyperopia. All other authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript.
